首页> 美国卫生研究院文献>The Journal of Molecular Diagnostics : JMD >A Novel DHPLC-Based Procedure for the Analysis of COL1A1 and COL1A2 Mutations in Osteogenesis Imperfecta
【2h】

A Novel DHPLC-Based Procedure for the Analysis of COL1A1 and COL1A2 Mutations in Osteogenesis Imperfecta

机译:一种基于DHPLC的新型方法用于分析成骨不全症中COL1A1和COL1A2突变

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Approximately 90% of patients with osteogenesis imperfecta (OI) exhibit dominant COL1A1 or COL1A2 mutations; however, molecular analysis is difficult because these genes span 51 and 52 exons, respectively. We devised a PCR-denaturing high-performance liquid chromatography (DHPLC) procedure to analyze the COL1A1 or COL1A2 coding regions and validated it using 130 DNA samples from individuals without OI, 25 DNA samples from two cells to investigate the procedure's potential for preimplantation diagnosis, and DNA samples from 10 patients with OI. Three novel intronic variants in vitro were expressed using a minigene assay to assess their effects on splicing. The procedure is rapid, inexpensive, and reproducible. Analysis of samples from individuals without OI revealed six novel and some known polymorphisms useful for linkage diagnosis because of high heterozygosity. Analysis of two-cell samples confirmed the known genotype in 24 of 25 experiments; DNA failed to amplify in only one case. No incidence of allele dropout was recorded. DHPLC revealed six novel mutations, three of which were intronic, in all patients with OI, and these results were confirmed by means of COL1A1 and COL1A2 direct sequencing. Expression of intronic mutations demonstrated that variant 804 + 2_804 + 3delTG in intron 11 disrupts normal splicing, thereby leading to formation of two alternative products. Variants c.3046-4_3046-5dupCT (COL1A1) and c.891 + 77A>T (COL1A2) did not affect splicing. The described DHPLC protocol combined with the minigene assay may contribute to molecular diagnosis in OI. Moreover, this protocol will aid in counseling about prenatal and preimplantation diagnosis.
机译:大约90%的成骨不全症(OI)患者表现出显性的COL1A1或COL1A2突变。但是,分子分析是困难的,因为这些基因分别跨越51和52个外显子。我们设计了一种PCR变性高效液相色谱(DHPLC)程序来分析COL1A1或COL1A2编码区,并使用130个没有OI的个体的DNA样品,两个细胞的25个DNA样品对其进行了验证,以研究该程序对植入前诊断的潜力,和10例OI患者的DNA样本。使用小基因测定法表达了三种体外新的内含子变异体,以评估它们对剪接的影响。该过程是快速,廉价且可重复的。对没有OI的个体进行的样品分析显示,由于高度杂合性,有六种新颖的和已知的多态性可用于连锁诊断。在25个实验中的24个中,对两细胞样品的分析证实了已知的基因型。 DNA仅在一种情况下无法扩增。没有记录到等位基因脱落的发生率。 DHPLC在所有OI患者中发现了6个新突变,其中3个是内含子突变,这些结果已通过COL1A1和COL1A2直接测序得到了证实。内含子突变的表达证明内含子11中的变体804 + 2_804 + 3delTG破坏了正常剪接,从而导致形成两种替代产物。 c.3046-4_3046-5dupCT(COL1A1)和c.891 + 77A> T(COL1A2)变体不影响剪接。所描述的DHPLC方案与小基因检测相结合可能有助于OI中的分子诊断。此外,该协议将有助于指导产前和植入前诊断。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号